Acetylcholinesterase Inhibitor Pharmacokinetics
From Proteopedia
(Difference between revisions)
| Line 60: | Line 60: | ||
! Metabolism | ! Metabolism | ||
! Hepatic (CYP2D6 & CYP3A4) & [[AChE]] | ! Hepatic (CYP2D6 & CYP3A4) & [[AChE]] | ||
| - | ! Hepatic (CYP1A2) & [[AChE] | + | ! Hepatic (CYP1A2) & [[AChE]] |
| - | ! [[AChE] | + | ! [[AChE]] |
| - | ! Hepatic (CYP3A4 & CYP2D6) & [[AChE] | + | ! Hepatic (CYP3A4 & CYP2D6) & [[AChE]] |
|} | |} | ||
For references, see: [[Treatments:AChE Inhibitor References|References]] | For references, see: [[Treatments:AChE Inhibitor References|References]] | ||
Revision as of 20:29, 9 December 2010
Pharmacokinetics
| Acetylcholinesterase Inhibitor Pharmacokinetics | ||||
|---|---|---|---|---|
| Parameter | Donepezil | Tacrine | Rivastigmine | Galantamine |
| Tmax (hr) | 3.6 | 1.5 | .3 | 1.2 |
| Cmax (ng/ml) | 6.5 | 15.7 | 29.3 | 42.6 |
| Bioavailability (%) | 100 | 17 | 36 | 100 |
| Protein Binding (%) | 96 | 55 | 40 | 10 |
| T1/2 (hr) | 70 | 3 | 5 | 7.3 |
| AUC (ng/ml/hr) | 380 | 80.4 | 191 | 427 |
| IC50 (nM) | 6.7 (Rat) | 450 (Human) | 1535 (Human) | 1995 (Rat) |
| Dosage (mg) | 5 | 160 | 6 | 8 |
| Metabolism | Hepatic (CYP2D6 & CYP3A4) & AChE | Hepatic (CYP1A2) & AChE | AChE | Hepatic (CYP3A4 & CYP2D6) & AChE |
For references, see: References
